This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reyes-Gibby, C. C. Articles by Shete, S. Search for Related Content PubMed PubMed Citation Articles by Reyes-Gibby, C. C. Articles by Shete, S.

Cytokine Genes and Pain Severity in Lung Cancer: Exploring the Influence of TNF--308 G/A IL6-174G/C and IL8-251T/A

¹ Department of Epidemiology, Division of Cancer Prevention, ² Palliative and Rehabilitation Medicine, ³ Phase I Program, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Cielito C. Reyes-Gibby, Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Unit 1340, 1155 Pressler Street, Houston, TX 77030-4009. Phone: 713-792-1816; Fax: 713-792-0807. E-mail: creyes{at}mdanderson.org

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Introduction: Cytokines, aberrantly produced by cancer cells, have recently been implicated in the severity of cancer-related pain. We explored if polymorphisms in candidate cytokine genes could explain variability in self-reported pain in lung cancer patients of all stages.

Methods: Pain, clinical, and demographic variables were assessed at presentation and before any cancer treatment in 446 Whites, 125 African-Americans, and 35 Hispanics with newly diagnosed non–small cell lung cancer. We genotyped functional single nucleotide polymorphisms in tumor necrosis factor- (TNF- -308 G/A), interleukin-6 (IL-6) -174G/C, and IL-8 -251T/A and determined their associations with pain severity.

Results: More African-Americans (35.5%) reported severe pain (score 7 on a 0-10 scale) relative to Hispanics (20%) and Whites (17%; P < 0.001). We did not observe any significant association between genotypes in TNF-, IL-6, and IL-8 and severe pain for either African-Americans or Hispanics, possibly due to small sample sizes. However, we observed that IL-8 (TT, 13%; TA + AA, 87%; P = 0.04) was significantly associated with severe pain among White patients. Logistic regression analyses showed that after controlling for epidemiologic (age and sex), clinical (stage of disease, comorbidities), and symptom (depressed mood and fatigue) variables known to influence pain severity, variant alleles in IL-8 -251T/A [odds ratio (OR), 2.35; 95% confidence interval (95% CI), 1.10-5.03; P = 0.03] persisted as a significant factor for severe pain for White patients.

Conclusions: In this preliminary analysis, we found evidence of the influence of cytokine genes on pain in White patients with lung cancer. Additional larger studies are needed to validate our findings. The long-term application is to tailored pain therapies. (Cancer Epidemiol Biomarkers Prev 2007;16(12):2745–51)

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cancer pain affects 17 million people worldwide. Lung cancer is one of the most common cancers to cause pain. Up to 50% of patients with small cell lung cancer (SCLC) report pain, and estimates increase to 65% for patients with non-SCLC (NSCLC; ref. 1). Cancer pain results from several mechanisms, including the primary activation of visceral or somatic nociceptors by a primary or metastatic tumor (nociceptive pain), impingement of the tumor on adjacent tissues, obstruction of blood vessels, or as a result of actual damage to the peripheral or central nervous system (neuropathic pain). More recently, studies suggest that inflammation caused by tumor-induced mediators, such as cytokines (2), may also be a potential mechanism for cancer-related pain.

Cytokines are soluble proteins or glycoproteins that act as mediators of cell-to-cell communications and are integral to the function of immune cells. Cytokines are pleiotropic, and their multiple overlapping functions depend on their local concentration, the type and the maturational stage of the responding cell, and the presence of other cytokines and their mediators.

The role of cytokines in the biology of various neoplastic disorders has been extensively studied. Cytokines are aberrantly produced by cancer cells, macrophages, and other phagocytic cells associated with tumor-producing cytokines (3, 4). These tumor-induced mediators are a potential mechanism for cancer-related cachexia, loss of appetite, or enhanced energy expenditure (5). More recently, research in the neurosciences suggests an important role of cytokines in cancer-related pain as well (6-9).

Variants in genes encoding for cytokines have been suggested as candidates for risk of a variety of cancers (3, 10-12), but their role has not been assessed in the epidemiology of cancer-related symptoms. We therefore explored the role of such variants in explaining the variability in pain in lung cancer patients.

Tumor necrosis factor- (TNF-) is a proinflammatory cytokine involved in the regulation of a wide spectrum of biological processes, including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. A neuroprotective function of this cytokine (13-15) and an important role in cancer-related symptoms including sickness-induced pain facilitation and enhancement have been suggested (8, 9). Genetic polymorphisms in the promoter region of the TNF- gene could modulate protein expression. Specifically, the G to A transition in the promoter region at position -308 has been shown to result in higher expression levels of TNF- in vitro and in vivo (10, 16).

Interleukin-6 (IL-6) is a proinflammatory cytokine released in response to infection, trauma, and neoplasia. It has a key role in immune and acute-phase response and hematopoesis. IL-6 exhibits a significant amount of pleiotropism and can modulate the effects of other cytokines and interact with glucocorticoids. The-174 G/C polymorphism is a single nucleotide polymorphism (SNP) that affects the transcription of the IL-6 gene, thus altering the serum levels of IL-6. Homozygotes for the G allele have been shown to have higher plasma IL-6 levels, higher IL-6 gene transcriptional activity, and higher inducible IL-6 responses than subjects homozygous for the C allele. The C allele has also been shown to be associated with adverse clinical outcomes such as less favorable prognosis after abdominal aortic aneurysms and poorer survival after sepsis (17-19).

IL-8 is a chemokine and one of the major mediators of the inflammatory response. IL-8 is secreted by several cell types, functions as a chemoattractant, and is also a potent angiogenic factor. IL-8 has also been shown to induce the production of other cytokines, including IL-6 and TNF- (20). The IL-8 gene is believed to play a role in the pathogenesis of cancer. Animal and human studies have begun to suggest its role in pain facilitation and enhancement. However, its association with symptom distress and other cancer-related symptoms is still speculative (21). The A allele of an IL-8 SNP in the promoter region (-251T/A) has been associated with increased IL-8 production (22).

In this preliminary analysis, we explored the extent to which functional polymorphisms in TNF- -308 G/A, IL-6 -174G/C, and IL-8 -251T/A are associated with the severity of pain using a sample of 446 Whites, 125 African-Americans, and 35 Hispanics with newly diagnosed, previously untreated patients with histologically confirmed lung cancer enrolled in an epidemiologic study of lung cancer. Lung cancer is a lethal disease marked by debilitating symptoms; understanding genetic factors associated with the severity of pain in lung cancer is crucial for early symptom intervention and may help inform treatment options.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Study Subjects
The study sample was drawn from an ongoing previously described case-control study of lung cancer (23). Case patients with histologically confirmed lung cancer who were newly diagnosed were recruited at the time of initial registration at the cancer center and before initiation of radiotherapy or chemotherapy. There were no restrictions with regard to age, sex, ethnicity, or disease stage. All cases were residents of the United States recruited from 1999 to 2005 and for whom pain and genetic data were available. (We selected this start date because from 1999, all patients are asked to respond to self-administered questionnaires on pain and quality of life during initial registration at the M.D. Anderson Cancer Center). The overall response rate for the study was 80%. This study was approved by the Institutional Review Board at M.D. Anderson Cancer Center, and all participants provided written informed consent.

Epidemiology, Symptoms, and Clinical Data Collection
Trained M.D. Anderson Cancer Center staff interviewers collected data on demographics, smoking history, and history of cancer. Patients rated their pain on an 11-point numerical scale, (0 = "no pain" and 10 = "pain as bad as you can imagine"). This item was taken from the Brief Pain Inventory, a recommended standard for pain assessment in clinical studies of pain (24). Because studies show a high correlation between depression, fatigue, and pain, we also assessed depressed mood and fatigue using the following items "during the past 4 weeks, have you felt downhearted and blue?" and "during the past 4 weeks, did you have a lot of energy?" These items were taken from the SF-12. The SF-12 is a validated measure of quality of life and is extensively used in studies of cancer patients (25-28). Patients rated these symptoms upon presentation at the M.D. Anderson Cancer Center before any cancer treatment. Clinical data, including stage of disease and history of comorbid conditions (heart disease, stroke, diabetes, etc.), were abstracted from patients' charts.

Blood Collection and Molecular Analysis
After the interview was completed, a 40-mL blood sample was drawn into coded heparinized tubes. Genomic DNA was extracted from peripheral blood lymphocytes by proteinase K digestion, followed by isopropanol extraction and ethanol precipitation. DNA samples were stored at –80°C. We did genotyping using a 5'-nuclease assay with dual fluorescent reporter probes VIC and FAM. The primer and probe sequences for each SNP can be found in the report by Landi et al. (29). Reactions were completed and read in a 7900 HT TaqMan sequence detector system (Applied Biosystems). Amplification mixes (5 µL) contained sample DNA (5 ng), 1x TaqMan buffer A, deoxynucleotide triphosphates (200 µmol/L), MgCl₂ (5 mmol/L), AmpliTaq Gold (0.65 units), each primer (900 nmol/L), and 200 nmol/L of each probe. The thermal cycling conditions consisted of one cycle for 10 min at 95°C, 40 cycles for 15 s at 95°C, and 40 cycles for 1 min at 60°C. Sequence Detector System (SDS) version 2.1 software (Applied Biosystems) was used to analyze end point fluorescence according to the allelic discrimination technique. Water control, ample internal controls, and previously genotyped samples were included in each plate to ensure the accuracy of genotyping.

Statistical Analyses
Descriptive statistics were used to summarize patient characteristics. The Kolmogorov-Smirnov Z test was used to assess normality distribution for pain severity. Because normality was not met, we used the National Comprehensive Cancer Network (NCCN) cutoff score for severe pain (30). A score 7/10 is considered as a pain emergency, and treatment is initiated with short-acting opioids.

Comparisons across specific genotypes and levels of pain were done using Pearson's ² analyses. Multivariable logistic regression analyses were done to assess the extent of association between the genotypes and severe pain. Variables found in the univariate analysis to be significantly associated with pain at a level of P < 0.20 (31) were included in the multivariable model. A P value of 0.20 was used as the cutoff because using a more traditional level (P < 0.05) might fail to identify variables known to be important (31). Further variable selection in the model was conducted by using a backward elimination approach. With the goal of having the most parsimonious model, only variables with P < 0.05 were included in the final multivariable model.

A significance level of 5% (two-sided) was used for the final analyses. Because of the multiplicity of tests conducted, this significance level can result in false-positive results; however, this level was considered acceptable for this exploratory study (32).

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Of the 695 patients with previously untreated and histologically confirmed lung cancer, 78% were White Caucasians and 21.7% were Hispanic, African-American, Asian, American-Indian, and of other ethnicities. A majority (95%) of the sample had histologically confirmed NSCLC, and only 5% (n = 30) presented with SCLC. Table 1A shows pain distribution for Caucasian whites, African-Americans, and Hispanics with NSCLC. The mean (4.33) and median (5.0) pain was highest for African-Americans, followed by Hispanics (mean = 3.2; median = 2.0) and lowest for Whites (mean = 2.9; median = 2.0). The Kolmogorov-Smirnov Z test showed that pain severity was not normally distributed for White (Z = 4.400; P = 0.0001), African-American (Z = 1.854; P = 0.0001), or Hispanic patients (Z = 1.660; P = 0.0001). Using NCCN guidelines for categorizations of pain severity, we observed that African-Americans (31.5%) had the highest proportion of patients reporting severe pain, followed by Hispanics (20%) and Whites (17%; P < 0.001).

TNF-

Self-Reported Pain and TNF-, IL-6, and IL-8
Table 2 shows the distribution of severe pain by genotype groups among Caucasian Whites. Assuming a dominant model, we observed that although a higher proportion of patients with variant alleles in TNF-, IL-6, and IL-8 reported severe pain, only IL-8 (TT = 13%; TA + AA = 87%; P = 0.04) was significantly associated with severe pain.

TNF-, IL-6

Univariate Analyses: Epidemiologic, Clinical, and Symptom Variables for Severe Pain in White Patients
Table 4 shows that the prevalence of severe pain significantly varied by stage of disease (early stage, 11%; advanced stage, 22%; P = 0.001); age (<50 years, 26%; 50 years, 14%; P = 0.01); sex (male, 14%; female, 20%; P = 0.05); depressed mood (none to mild, 15%; moderate to severe, 41%; P = 0.001); and fatigue (none to mild, 8%; moderate to severe, 28%; P = 0.001). None of the comorbid conditions were associated with severe pain.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
Studies of cancer-related pain have traditionally focused on the influence of disease-related variables (stage of disease), clinical health status (performance status, comorbid conditions), and sociodemographic characteristics (age, gender, race, and marital status). This study assessed the contribution of genetic variation in select cytokine genes to the severity of pain in a large sample of patients newly diagnosed with NSCLC. We found that both genetic and nongenetic factors were relevant in the severity of pain and specifically found an association between polymorphisms in IL-8 and severe pain in whites. To our knowledge, this is among the first studies to provide preliminary evidence that functional polymorphisms in cytokine genes associated with increased gene expression are associated with higher levels of pain in a large sample of White patients newly diagnosed with lung cancer.

Although the exact molecular mechanism by which cytokines influence pain has not been fully elucidated, studies suggest that cytokines released during inflammation or tissue damage (as in the cancer process) modify the activity of nociceptors contributing to pain hypersensitivity. Clinical studies show elevated IL-8 levels in patients with chronic pain conditions such back pain (33), post-herpetic neuralgia (34), and unstable angina (35). In animal studies, Cunha et al. (36) measured the hyperalgesic effect of IL8 in a rat paw pressure test and found that IL-8 evoked dose-dependent hyperalgesia. The hyperalgesia was blocked by specific anti–IL-8 serum, suggesting that IL-8 causes hyperalgesia. Ribeiro et al. (37) also observed that i.p. administration of a specific antiserum against IL-8 partly blocked the nociceptive response in mice. Other studies suggest that chemokines including IL-8 may produce enhanced sensitivity to pain via direct actions on chemokine receptors expressed by nociceptive neurons (38).

The observed allele frequencies in our population were similar to other studies (39, 40). Consistent with our findings, the presence of the -251A allele in IL-8 has been associated with adverse clinical outcomes, including colorectal adenoma (40) and gastric cancer (39). Studies have also suggested that other cytokines, such as proinflammatory IL-6 and TNF-, cause hyperexcitability in pain transmission neurons, and the exaggerated release of substance P and excitatory amino acids from presynpatic terminals produces an exaggerated pain response (7, 41). However, we did not observe a relationship between TNF, IL-6, and pain severity in this study. Of note is that IL-8 has been shown to induce the production of other cytokines such as IL-6 and TNF- (20).

We found depressed mood and fatigue as significant correlates of pain in the univariate analyses, and this pattern persisted even when we took into account the impact of coexisting medical conditions and sociodemographic factors. Pain, depression, and fatigue are typically experienced as the most prevalent symptoms among patients with cancer, and many have argued that because they occur as a cluster of symptoms or as a pain syndrome, there may be a shared biological mechanism for these symptoms. Because inflammatory cytokines have been associated not only with pain but also with depression and fatigue, it might be possible that in a polygenic model for pain, other cytokines involved in the modulation of nociceptive input are also related to fatigue and depression. Future studies should measure the frequency and severity of depressed mood/depression and fatigue in patients with cancer pain.

It is also important to note that other studies have addressed the relationship of depression and pain and have found depression as having either a causal or a mediating effect on pain (42). However, we were unable to assess the directionality of the relationship between depressed mood and severe pain due to the cross-sectional nature of our data set. Prospective studies are needed to assess if these symptoms covary over the course of the disease process. Importantly, our analyses showed that genetic polymorphism in IL-8 remained as a significant factor for pain severity, independent of the effect of depressed mood and fatigue.

Consistent with other studies, we found that ethnic minorities, those with advanced stage of disease, and younger age were more likely to report severe pain relative to their counterparts. In a population-based study of cancer survivors, non-Hispanic African-Americans (OR, 1.78; 99% CI, 1.33-2.37) and Hispanics (OR, 1.80; 99% CI, 1.26-2.56) were found to have higher risk for severe pain compared with non-Hispanic whites (43). Studies also show that up to 40% of patients receiving active cancer treatment report pain, and these increase to 80% for patients with advanced cancer (44, 45). It is also documented that whereas older patients are more likely to experience pain, they are less likely to complain of pain (46).

There are limitations to our study. We lack data on analgesic intake, and thus, we were unable to adjust for its potential confounding effect in the analyses. Another limitation is that using a single item to measure pain, depressed mood, and fatigue may be an inadequate assessment of these symptoms. It should be noted, however, that other studies have found that single-item questions correlate well with assessment tools for fatigue and depression (47, 48).

Many have also argued for the need for a polygenic model for pain and pain-related phenotypes. Ideally, many genes with functional significance should be assessed, especially because it is known that there is considerable interaction between different cytokines, forming networks that initiate gene activation and suppression (49). It is also important to note that inclusion of multiple SNPs per gene would have allowed examination of haplotypes, which may have provided different outcomes. In addition, the tested SNP may not necessarily be the functional SNP, but may be in linkage disequilibrium with the true functional SNP. We also have a very small sample of African-Americans and Hispanics in our study. Given that ethnic minorities are at higher risk for severe pain, additional studies are needed to further explore the association between severe pain and cytokine genes in these populations.

In conclusion, modest improvements in the survival rates of patients with lung cancer have been observed in recent years. However, the majority of patients still suffer from both disease- and treatment-related symptoms. Previous studies have focused on clinical health status and sociodemographic characteristics in understanding cancer-related pain. Because genetic polymorphisms are stable markers, our observation that genetic differences in cytokine genes is a significant correlate of pain may prove useful in developing risk models for pain and, importantly, in developing personalized therapies. Furthermore, with experimental studies on cytokine receptor antagonists or other cytokine inhibitors currently under way, the use of genetic polymorphisms, arguably stable markers for cytokine function, could help in understanding patients who might benefit most from symptom intervention using cytokine products. Our findings need to be validated in large, prospectively accrued populations and incorporating additional genetic markers in the cytokine pathway.

	Footnotes

 
Grant support: C.C. Reyes-Gibby is a recipient of K07CA109043 from the NIH/National Cancer Institute (NCI), and M. Spitz is a recipient of CA55769 (NIH/NCI).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/25/07; revised 9/15/07; accepted 10/ 2/07.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Hopwood P, Thatcher N. Preliminary experience with quality of life evaluation in patients with lung cancer. Oncology (Huntingt) 1990;4:158–62.[Medline]
2. Maier SF, Watkins LR. Immune-to-central nervous system communication and its role in modulating pain and cognition: implications for cancer and cancer treatment. Brain Behav Immun 2003;17 Suppl 1:S125–31.[CrossRef][Medline]
3. Jin P, Panelli MC, Marincola FM, Wang E. Cytokine polymorphism and its possible impact on cancer. Immunol Res 2004;30:181–90.[CrossRef][Medline]
4. Kurzrock R. Cytokine deregulation in cancer. Biomed Pharmacother 2001;55:543–7.[CrossRef][Medline]
5. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001;92:1684–8.[CrossRef][Medline]
6. Watkins LR, Maier SF. Implications of immune-to-brain communication for sickness and pain. Proc Natl Acad Sci U S A 1999;96:7710–3.[Abstract/Free Full Text]
7. Watkins LR, Maier SF. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern Med 2005;257:139–55.[CrossRef][Medline]
8. Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain 1995;63:289–302.[CrossRef][Medline]
9. Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF. Characterization of cytokine-induced hyperalgesia. Brain Res 1994;654:15–26.[CrossRef][Medline]
10. Azmy IA, Balasubramanian SP, Wilson AG, et al. Role of tumour necrosis factor gene polymorphisms (-308 and -238) in breast cancer susceptibility and severity. Breast Cancer Res 2004;6:R395–400.[Medline]
11. Howell WM, Calder PC, Grimble RF. Gene polymorphisms, inflammatory diseases and cancer. Proc Nutr Soc 2002;61:447–56.[CrossRef][Medline]
12. Howell WM, Rose-Zerilli MJ. Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 2006;5:143–9.[CrossRef][Medline]
13. Bruce AJ, Boling W, Kindy MS, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 1996;2:788–94.[CrossRef][Medline]
14. Quintana A, Giralt M, Rojas S, et al. Differential role of tumor necrosis factor receptors in mouse brain inflammatory responses in cryolesion brain injury. J Neurosci Res 2005;82:701–16.[CrossRef][Medline]
15. Sullivan PG, Bruce-Keller AJ, Rabchevsky AG, et al. Exacerbation of damage and altered NF-B activation in mice lacking tumor necrosis factor receptors after traumatic brain injury. J Neurosci 1999;19:6248–56.[Abstract/Free Full Text]
16. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997;94:3195–9.[Abstract/Free Full Text]
17. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369–76.[Medline]
18. Haukim N, Bidwell JL, Smith AJ, et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun 2002;3:313–30.[CrossRef][Medline]
19. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000;275:18138–44.[Abstract/Free Full Text]
20. Franciosi S, Choi HB, Kim SU, McLarnon JG. IL-8 enhancement of amyloid-β (Abeta 1-42)–induced expression and production of pro-inflammatory cytokines and COX-2 in cultured human microglia. J Neuroimmunol 2005;159:66–74.[CrossRef][Medline]
21. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000;55:1023–7.[Abstract/Free Full Text]
22. Puthothu B, Krueger M, Heinze J, Forster J, Heinzmann A. Impact of IL8 and IL8-receptor polymorphisms on the genetics of bronchial asthma and severe RSV infections. Clin Mol Allergy 2006;4:2.[CrossRef][Medline]
23. Wei Q, Cheng L, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000;92:1764–72.[Abstract/Free Full Text]
24. Caraceni A, Cherny N, Fainsinger R, et al. Pain measurement tools and methods in clinical research in palliative care: recommendations of an expert working group of the European Association of Palliative Care. J Pain Symptom Manage 2002;23:239–55.[CrossRef][Medline]
25. Vilaseca I, Chen AY, Backscheider AG. Long-term quality of life after total laryngectomy. Head Neck 2006;28:313–20.[Medline]
26. Ware J, Jr., Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220–33.[CrossRef][Medline]
27. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56:899–905.[CrossRef][Medline]
28. Wettergren L, Bjorkholm M, Axdorph U, Langius-Eklof A. Determinants of health-related quality of life in long-term survivors of Hodgkin's lymphoma. Qual Life Res 2004;13:1369–79.[Medline]
29. Landi S, Moreno V, Gioia-Patricola L, et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor , NFKB1, and peroxisome proliferator-activated receptor with colorectal cancer. Cancer Res 2003;63:3560–6.[Abstract/Free Full Text]
30. National Comprehensive Cancer Network [homepage on the Internet] [updated 2007 July 07; cited 2007 Sept. 12]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/pain.pdf.
31. Bendel RB, Afifi AA. Comparison of stopping rules in forward regression. Journal of the American Statistical Association 1977;72:46–53.[CrossRef]
32. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43–6.[Medline]
33. Brisby H, Olmarker K, Larsson K, Nutu M, Rydevik B. Proinflammatory cytokines in cerebrospinal fluid and serum in patients with disc herniation and sciatica. Eur Spine J 2002;11:62–6.[CrossRef][Medline]
34. Kotani N, Kudo R, Sakurai Y, et al. Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia. Am J Med 2004;116:318–24.[CrossRef][Medline]
35. Zhou RH, Shi Q, Gao HQ, Shen BJ. Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. J Atheroscler Thromb 2001;8:30–2.[Medline]
36. Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH. Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol 1991;104:765–7.[Medline]
37. Ribeiro RA, Vale ML, Thomazzi SM, et al. Involvement of resident macrophages and mast cells in the writhing nociceptive response induced by zymosan and acetic acid in mice. Eur J Pharmacol 2000;387:111–8.[CrossRef][Medline]
38. Oh SB, Tran PB, Gillard SE, Hurley RW, Hammond DL, Miller RJ. Chemokines and glycoprotein 120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 2001;21:5027–35.[Abstract/Free Full Text]
39. Garza-Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI, Flores-Gutierrez JP, Maldonado-Garza HJ, Perez-Perez GI. Assessment of the toll-like receptor 4 Asp²⁹⁹Gly, Thr³⁹⁹Ile and interleukin-8 -251 polymorphisms in the risk for the development of distal gastric cancer. BMC Cancer 2007;7:70.[CrossRef][Medline]
40. Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2006;15:1126–31.[Abstract/Free Full Text]
41. Maier SF, Watkins LR. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998;105:83–107.[CrossRef][Medline]
42. Turk DC, Okifuji A, Scharff L. Chronic pain and depression: role of perceived impact and perceived control in different age cohorts. Pain 1995;61:93–101.[CrossRef][Medline]
43. Reyes-Gibby CC, Aday LA, Anderson KO, Mendoza TR, Cleeland CS. Pain, depression, and fatigue in community-dwelling adults with and without a history of cancer. J Pain Symptom Manage 2006;32:118–28.[Medline]
44. Bruera E, Neumann C, Brenneis C, Quan H. Frequency of symptom distress and poor prognostic indicators in palliative cancer patients admitted to a tertiary palliative care unit, hospices, and acute care hospitals. J Palliat Care 2000;16:16–21.[Medline]
45. Elsayem A, Swint K, Fisch MJ, et al. Palliative care inpatient service in a comprehensive cancer center: clinical and financial outcomes. J Clin Oncol 2004;22:2008–14.[Abstract/Free Full Text]
46. Reyes-Gibby CC, Aday L, Cleeland C. Impact of pain on self-rated health in the community-dwelling older adults. Pain 2002;95:75–82.[CrossRef][Medline]
47. Bellamy N, Campbell J, Syrotuik J. Comparative study of self-rating pain scales in osteoarthritis patients. Curr Med Res Opin 1999;15:113–9.[Medline]
48. Jensen MP, McFarland CA. Increasing the reliability and validity of pain intensity measurement in chronic pain patients. Pain 1993;55:195–203.[CrossRef][Medline]
49. Keen LJ. The extent and analysis of cytokine and cytokine receptor gene polymorphism. Transpl Immunol 2002;10:143–6.[CrossRef][Medline]

This article has been cited by other articles:

				C. C. Reyes-Gibby, B. El Osta, M. R. Spitz, H. Parsons, R. Kurzrock, X. Wu, S. Shete, and E. Bruera The Influence of Tumor Necrosis Factor-{alpha} -308 G/A and IL-6 -174 G/C on Pain and Analgesia Response in Lung Cancer Patients Receiving Supportive Care Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3262 - 3267. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reyes-Gibby, C. C. Articles by Shete, S. Search for Related Content PubMed PubMed Citation Articles by Reyes-Gibby, C. C. Articles by Shete, S.